<DOC>
	<DOCNO>NCT00984282</DOCNO>
	<brief_summary>Trial sorafenib versus placebo treatment locally advance metastatic differentiate thyroid cancer refractory radioiodine</brief_summary>
	<brief_title>NexavarÂ® Versus Placebo Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer</brief_title>
	<detailed_description>Eligible subject randomize 1:1 sorafenib 800 mg daily match placebo . Progression assess every 8 week modify RECIST criterion . Subjects option unblind study treatment progression receive open label sorafenib regardless initial treatment assignment . Following discontinuation study treatment , subject follow survival every 3 month long-term follow-up . Subjects terminate study treatment ( either double double blind open label ) reason death , lose follow-up consent withdrawn enter long-term follow</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Locally advanced metastatic differentiate thyroid cancer ( papillary , follicular Hurthle cell ) Poorly differentiate thyroid variant ( e.g . insular , tall cell , etc . ) eligible provide histology medullary differentiation anaplastic feature Progression within 14 month ( RECIST [ Response Evaluation Criteria Solid Tumors ] use basis assessment disease progression ) RAI ( radioactive iodine ) refractory Histologic subtypes thyroid cancer differentiate ( i.e . like anaplastic medullary carcinoma , lymphoma sarcoma ) Prior anticancer treatment tyrosine kinase inhibitor , monoclonal antibody ( licensed investigational ) target VEGF ( vascular endothelial growth factor ) VEGF Receptors target agent Prior anticancer treatment thyroid cancer use chemotherapy ( low dose chemotherapy radiosensitization allow ) Thalidomide derivative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>RAI-Refractory</keyword>
	<keyword>Differentiated</keyword>
	<keyword>Follicular</keyword>
	<keyword>Papillary</keyword>
	<keyword>Hurthle</keyword>
</DOC>